Quality of life of glaucoma patients under medical therapy with different prostaglandins

Clinical Ophthalmology

Volumn 6, Issue 1, 2012, Pages 1749-1753

  Guedes, Ricardo Augusto Paletta ^a,b,c   Guedes, Vanessa Maria Paletta ^a,b,c   Freitas, Sirley Maria ^b   Chaoubah, Alfredo ^a  

^a FEDERAL UNIVERSITY OF JUIZ DE FORA   (Brazil)

^b Paletta Guedes Ophthalmological Center   (Brazil)

^c Santa Casa de Misericórdia Hospital   (Brazil)

Author keywords

Glaucoma; Medical treatment; Prostaglandin analogs; Quality of life

Indexed keywords

BIMATOPROST; LATANOPROST; PROSTAGLANDIN DERIVATIVE; TRAVOPROST;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; COLOR VISION; CROSS-SECTIONAL STUDY; DRUG USE; EYE PAIN; FEMALE; GLAUCOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; NATIONAL EYE INSTITUTE VISUAL FUNCTION QUESTIONNAIRE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PERIPHERAL VISION; QUALITY OF LIFE; SOCIAL STATUS;

EID: 84869239118     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S37347     Document Type: Article

References (18)

1. Resnikoff S, Pascolini D, Etya'ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004;82:844-851.
2. European Glaucoma Society. Terminology and Guidelines for Glaucoma, 2nd ed. Savona, Italy: Ed Dogma; 2003.
3. Emerick GT. Quality of life and glaucoma medications. Do our proescriptions make a difference? Glaucoma Today. 2005;5:38-39.
4. Aptel F, Cucherat M, Denis P. Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials. J Glaucoma. 2008;17:667-673.
5. Honrubia F, Garcia-Sanchez J, Polo V, de la Casa JM, Soto J. Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomized clinical trials. Br J Ophthalmol. 2009;93: 316-321.
6. Zimmerman TJ, Stewart WC, Latanoprost Axis Study Group. Intra-ocular pressure, safety and quality of life in glaucoma patients switching to latanoprost from monotherapy treatments. J Ocul Pharmacol Ther. 2003;19:405-415.
7. Balkrishnan R, Bond JB, Byerly WG, Camacho FT. Medication-related predictors of health-related quality of life in glaucoma patients enrolled in a Medicare health maintenance organization. Am J Geriatr Pharmacother. 2003;1:75-81.
8. Hodapp E, Parrish RK, Anderson DR. Clinical Decisions in Glaucoma. St Louis, MO: Mosby; 1993.
9. Simao LM, Lana-Peixoto MA, Araújo CR, Moreira MA, Teixeira AL. The Brazilian version of the 25-item National Eye Institute Visual Function Questionnaire: translation, reliability and validity. Arq Bras Oftalmol. 2008;71:540-546.
10. Sawada H, Fukuchi T, Abe H. Evaluation of the relationship between quality of vision and visual function in Japanese glaucoma patients. Clin Ophthalmol. 2011;5:259-267.
11. Janz NK, Wren PA, Lichter PR, et al. The Collaborative Initial Glaucoma Treatment Study: interim quality of life findings after initial medical or surgical treatment of glaucoma. Ophthalmology. 2001;108:1954-1965.
12. Ramulu P. Glaucoma and disability: which tasks are affected, and at what stage of disease? Curr Opin Ophthalmol. 2009;20:92-98.
13. Sharma S, Brown GC, Brown MM, et al. Converting visual acuity to utilities. Can J Ophthalmol. 2000;35:267-272.
14. Noecker RJ, Walt JG. Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications. Am J Ophthalmol. 2006;141:S15-S21.
15. Reardon G, Schwartz GF, Mozzafari E. Patient persistency with topical ocular hypotensive therapy in a managed care population. Am J Ophthalmol. 2004;137:S3-S12.
16. Reardon G, Schwartz GF, Kotak S. Persistence on prostaglandin ocular hypotensive therapy: an assessment using medication possession and days covered on therapy. BMC Opthahlmol. 2010;2:10-15.
17. Suzuki ER, Suzuki CL. Efficacy and safety of travoprost alone or in combination with other agents for glaucoma and ocular hypertension: patient considerations. Clin Ophthalmol. 2010;21:1165-1171.
18. Hommer A. A review of preserved and preservative-free prostaglandin analogues for the treatment of open angle glaucoma and ocular hypertension. Drugs Today (Barc). 2010;6:409-416.